A Proteolytic Cascade Controls Lysosome Rupture and Necrotic Cell Death Mediated by Lysosome-Destabilizing Adjuvants

Jürgen Brojatsch*, Heriberto Lima Jr.*, Alak K. Kar*, Lee S. Jacobson*, Stefan M. Muehlbauer*, Kartik Chandran, Felipe Diaz-Griffero

Abstract
Recent studies have linked necrotic cell death and proteolysis of inflammatory proteins to the adaptive immune response mediated by the lysosome-destabilizing adjuvants, alum and Leu-Leu-OMe (LLOMe). However, the mechanism by which lysosome-destabilizing agents trigger necrosis and proteolysis of inflammatory proteins is poorly understood. The proteasome is a cellular complex that has been shown to regulate both necrotic cell death and proteolysis of inflammatory proteins. We found that the peptide aldehyde proteasome inhibitors, MG115 and MG132, block lysosome rupture, degradation of inflammatory proteins and necrotic cell death mediated by the lysosome-destabilizing peptide LLOMe. Additionally, non-aldehyde proteasome inhibitors failed to prevent LLOMe-induced cell death suggesting that aldehyde proteasome inhibitors triggered a pleotropic effect. We have previously shown that cathepsin C controls lysosome rupture, necrotic cell death and the adaptive immune response mediated by LLOMe. Using recombinant cathepsin C, we found that aldehyde proteasome inhibitors directly block cathepsin C, which presumably prevents LLOMe toxicity. The cathepsin B inhibitor CA-074-Me also blocks lysosome rupture and necrotic cell death mediated by a wide range of necrosis inducers, including LLOMe. Using cathepsin-deficient cells and recombinant cathepsins, we demonstrate that the cathepsins B and C are not required for the CA-074-Me block of necrotic cell death. Taken together, our findings demonstrate that lysosome-destabilizing adjuvants trigger an early proteolytic cascade, involving cathepsin C and a CA-074-Me-dependent protease. Identification of these early events leading to lysosome rupture will be crucial in our understanding of processes controlling necrotic cell death and immune responses mediated by lysosome-destabilizing adjuvants.

Introduction
While research on programmed cell death has focused mainly on apoptosis, recent studies have highlighted the relevance of necrotic cell death in many biological and immunological processes. For example, necrotic cell death has been implicated in microbial pathogenesis, septic shock and adaptive immune responses [1,2,3,4,5,6,7,8]. While apoptotic cells retain their intracellular content, necrotic cell death is characterized by plasma membrane impairment and the release of intracellular factors driving inflammatory responses. Specifically, the necrotic release of uric acid, MHGB1, double-stranded DNA, and ATP has been linked to immune responses mediated by necrotic cell death inducers [9,10,11,12,13,14].

While necrosis was originally considered a traumatic disregulated process caused by direct chemical or radiologic insult [15], recent studies indicate that necrotic cell death is, like apoptosis, a highly regulated process with inducer-specific checkpoints [7,16]. For example, pyroptosis, the best-characterized form of necrosis, requires caspase-1 activation and inflammasome signaling [16,17,18,19,20,21]. The second form of necrotic cell death, necroptosis, is induced by specific death receptors, such as TNF-α and Trail, in the presence of caspase inhibitors [22,23]. Recent studies indicate that lysosome-destabilizing agents mediate a third form of programmed necrosis, termed as lysosome-mediated necrosis (LMN) [9,24,25,26,27]. Inducers of LMN include alum, silica crystals, cholesterol crystals, amyloid proteins, and the dipeptide methyl ester Leu-Leu-OMe (LLOMe) [9,24,28].

Though all forms of necrotic cell death have been linked to inflammation, only LMN has specifically been linked to the induction of the adaptive immunity [9,11,28]. LMN is characterized by early lysosome-rupture followed by plasma membrane impairment and proteolysis of low-molecular-weight point proteins [11,24]. As a result, several key inflammatory proteins, including caspase-1, IL-1β and IL-18, are degraded, decreasing their signal [11,24]. Prior studies have elicited three cathepsins as critical...
regulators of lysosome-mediated necrosis: cathepsin C is crucial for LLOMe-mediated necrosis, while cathepsins B and S are necessary for alum-mediated necrosis [9,11,28]. The mechanism by which lysosome-destabilizing agents trigger proteolysis of cytosolic proteins and plasma membrane impairment remains unclear.

Previous studies have linked the proteasome system to proteolysis of inflammatory proteins and programmed cell death [29,30,31,32]. The ubiquitin-proteasome pathway is a major proteolytic system in eukaryotic cells, and responsible for degrading proteins flagged by ubiquitin moieties [33]. The proteasome system is also a critical regulator of multiple forms of necrotic and apoptotic cell death [29,30]. Specifically, the proteasome system controls lysosome rupture, necrotic cell death and proteolysis of inflammatory proteins mediated by the pyroptosis inducer anthrax lethal toxin (LT) [29,31,32]. Here we investigated the extent to which the proteasome also regulates cell death and proteolysis of cellular proteins in lysosome-mediated necrosis. Here we report that the aldehyde proteasome inhibitors, MG115 and MG132, block the degradation of proinflammatory proteins and necrotic cell death mediated by LLOMe. Using a combination of cellular, genetic, and biochemical models we present evidence lysosome-mediated necrosis is a proteasome-independent process, but that aldehyde proteasome inhibitors target cathepsin C, a protein previously shown to be critical for LLOMe-mediated lysosome rupture. In contrast to aldehyde proteasome inhibitors, the broad necrosis inhibitor CA-074-Me blocked LLOMe-induced lysosome rupture and necrotic cell death without targeting cathepsins C. Taken together our findings indicated that aldehyde proteasome inhibitors and CA-074-Me target distinct proteins involved in a proteolytic cascade preceding lysosome rupture and necrotic cell death mediated by lysosome-disrupting adjuvants.

Results and Discussion

The proteasome inhibitor MG115 inhibits cell death and proteolysis of inflammatory proteins mediated by the lysosome-destabilizing adjuvant LLOMe

Recent studies have demonstrated that necrotic cell death mediated by lysosome-destabilizing agents induces a strong adaptive immune response [9,11,28]. While necrotic cell death and proteolysis of inflammatory proteins have been linked to the immunogenicity of lysosome-disrupting adjuvants [9,11,12,24], the underlying cellular mechanisms that control these processes are poorly understood. We have previously shown that the ubiquitin-proteasome system is critical for necrotic mediated by anthrax lethal toxin (LT), but not by other necrosis inducers, such as LPS/nigericin [29,31,32,34]. To determine whether the proteasome also controls necrotic and proteolytic processes mediated by lysosome-destabilizing agents, we treated primary bone marrow-derived murine macrophages with the lysosome-destabilizing adjuvants alum and Leu-Leu-OMe (LLOMe) in the presence and absence of the peptide aldehyde proteasome inhibitor MG115 [9,24,28]. As controls we used the inducers of pyroptotic cell death, anthrax lethal toxin and LPS/nigericin. We found that the proteasome inhibitor MG115 efficiently blocked necrotic cell death mediated by LLOMe (Figure 1A and 1B). MG115 not only blocked cell death but also proteolysis of the inflammatory protein caspase-1 in LLOMe-treated macrophages (Figure 1C). MG115 also blocked cell death by anthrax lethal toxin, as shown previously [29,31,32,34,35], but failed to block cell death mediated by LPS/nigericin and by the lysosome-destabilizing agent alum (Figure 1A and 1B). As an additional control, we used the cathepsin B inhibitor CA-074-Me, which blocks all forms of programmed necrotic cell death [9,22,29,36]. Consistent with being a pan-necrosis inhibitor, CA-074-Me blocked cell death mediated by the lysosome-destabilizing agents, alum and LLOMe, and by the pyroptosis inducers, LT and LPS/ATP (Figure 1A). Taken together, our findings indicated that aldehyde proteasome inhibitor MG115 blocks necrotic cell death in an inducer-specific fashion.

Peptide-aldehyde proteasome inhibitors block LMN while non-aldehyde proteasome inhibitors do not

In order to delineate the role of proteasome in necrotic cell death, we exposed BALB/c-derived macrophages to LLOMe and LT in the presence of increasing amounts of peptide aldehyde and high-potency non-peptide aldehyde proteasome inhibitors. We found that the peptide aldehyde proteasome inhibitors, MG115 and MG132, blocked LLOMe-mediated cell death at concentrations above 25 μM, while inhibitor concentrations as low as 1 μM were sufficient to block LT-induced cell death (Figure 2A and Figure S1). Intriguingly, the non-peptide aldehyde proteasome inhibitors, bortezomib (Velcade) (Figure 2A) and Salinosporamide (data not shown) failed to block LLOMe-mediated necrosis even at concentrations above 100 μM. Consistent with proteasome involvement in LT toxicity, bortezomib blocked LT-induced cell death at nanomolar concentrations (Figure 2B). The failure of bortezomib and Salinosporamide to block LLOMe-induced cell death suggested that cellular systems other than the proteasome control LLOMe-induced necrotic cell death.

MG115 inhibits cathepsin C activity

Using a haploid screen, we have previously shown that a single protease, cathepsin C, is critical for the induction of cell death and the adaptive immune response mediated by LLOMe [9]. To date cathepsin C is the only critical mediator of LLOMe-mediated cell death that has been identified [9]. As peptide aldehyde proteasome inhibitors block LLOMe-induced cell death in a proteasome-independent fashion, we investigated whether the inhibitors might prevent LLOMe toxicity by directly targeting cathepsin C. To this hypothesis, we incubated recombinant murine cathepsin C with the cathepsin C substrate Gly-Arg-AMC (GR-AMC) in the presence of increasing concentrations of MG115. As postulated, the proteasome inhibitor MG115 blocked the activity of recombinant cathepsin C (Figure 3A), as indicated by reduced release of the fluorescent AMC moiety in the presence of MG115 [37]. We found that MG115 concentrations that blocked cathepsin C activity also prevented LLOMe-mediated cell death (Figure 3A and B). As MG115 blocked cell death and cathepsin C activity at similar concentrations, it was reasonable to assume that the inhibitor blocked LLOMe-mediated cell death by directly targeting cathepsin C. As a positive control, we used the cathepsin C-specific inhibitor Gly-Phe-DMK (GF-DMK), which efficiently blocked cathepsin C activity at concentrations below 1 μM (Figure 3A). As seen with MG115, GF-DMK blocked LLOMe-induced cell death and cathepsin C activity at similar concentrations (Figure 3A and B). Our studies using MG115 in the recombinant cathepsin C assay were consistent with a central role of cathepsin C in LLOMe toxicity.

Proteasome inhibitors block lysosome rupture mediated by the lysosome-destabilizing agent LLOMe

As aldehyde proteasome inhibitors blocked recombinant cathepsin C in vitro, we next wanted to determine whether these inhibitors also block cathepsin C in vivo. Multiple studies have
suggested that the carboxypeptidase activity of cathepsin C converts the dipeptide-methyl ester LLOMe into a membranolytic polymer responsible for lysosome rupture and cell death induction [9,38,39]. We therefore expected that aldehyde peptide inhibitors block lysosome rupture mediated by LLOMe. To address this question, we exposed primary murine macrophages to the lysosome-destabilizing agents, LLOMe and alum, and to the pyroptosis inducer LT in the presence of proteasome inhibitors. We quantified lysosomal integrity by flow cytometry using the lysosomal pH-indicators LysoTracker and acridine orange (AO). Multiple labs, including our own, have previously shown that the loss of pH gradients in cells treated with alum and LLOMe is

Figure 1. The proteasome inhibitor MG115 blocks LLOMe-mediated cell death and protein degradation. (A) BALB/c-derived macrophages were primed with 250 ng/ml LPS for 2 hours, and then treated with 2.5 mM LLOMe, anthrax lethal toxin (LT: 500 ng/ml PA and 250 ng/ml LF), alum (150 μg/ml), or 10 μM nigericin (LN) in the absence or presence of 100 μM MG115 or 100 μM CA-074-Me. Cell death was measured after 2 hours (except for alum, which was exposed for 8 hours) by propidium iodide exclusion. Relative levels are blotted with inducer alone adjusted to 100% cell death. (B) BALB/c-derived macrophages were exposed to 2.5 mM LLOMe (LL) or anthrax lethal toxin (500 ng/ml PA and 250 ng/ml LF) in the absence or presence of 100 μM MG115 (MG). Cell death was measured by propidium iodide exclusion. (C) BALB/c macrophages were exposed to 2.5 mM LLOMe in the absence or presence of 100 μM MG115. Cellular lysates were isolated at different time points after LLOMe exposure, and were subjected to immunoblotting and probed with anti-caspase-1 and actin antibodies.

doi:10.1371/journal.pone.0095032.g001

Figure 2. Effect of proteasome inhibitors on cell death mediated by LLOMe and anthrax lethal toxin (LT). BALB/c-derived macrophages were exposed to 2.5 mM LLOMe (A) or anthrax lethal toxin (500 ng/ml PA and 250 ng/ml LF) (B) in the presence of increasing concentrations of the aldehyde proteasome inhibitors, MG115 and MG132, and the non-aldehyde proteasome inhibitor bortezomib. Cell death was measured by PI exclusion two hours after LLOMe/LT exposure. The above data is a representative experiment performed in triplicate.

doi:10.1371/journal.pone.0095032.g002
LLOMe exposure.

DMK, and cell death was measured by PI exclusion two hours after LLOMe in the presence of increasing concentrations of MG115 or GF-DMK. (B) C57BL/6-derived macrophages were exposed to 2.5 mM Cathepsin C activity was measured by analyzing Gly-Arg-AMC cleavage at 460 nm. (A) The cathepsin C assay was performed in the presence of 1 ng recombinant cathepsin C, a diffuse cytosolic and nuclear staining upon LLOMe exposure

as expected, MG115 blocked lysosome rupture in LLOMe-treated macrophages (Figure 4A). Consistent with earlier findings, this block was specific to the peptide aldehyde proteasome inhibitor MG115, while the non-peptide aldehyde proteasome inhibitor bortezomib failed to block LLOMe-induced lysosome rupture (Figure 4A). Bortezomib, however, prevented lysosome impairment mediated by LT consistent with a role of the proteasome in LT toxicity (Figure 4A). As expected, MG115 and bortezomib failed to block LLOMe-induced cell death, and cell death was measured by PI exclusion two hours after LLOMe exposure. doi:10.1371/journal.pone.0095032.g003 concurrent with actual lysosome rupture [9,24,28]. We therefore used LysoTracker and AO to monitor lysosome integrity in cells exposed to lysosome-destabilizing agents.

As expected, MG115 blocked lysosome rupture in LLOMe-treated macrophages (Figure 4A). Consistent with earlier findings, this block was specific to the peptide aldehyde proteasome inhibitor MG115, while the non-peptide aldehyde proteasome inhibitor bortezomib failed to block LLOMe-induced lysosome rupture (Figure 4A). Bortezomib, however, prevented lysosome impairment mediated by LT consistent with a role of the proteasome in LT toxicity (Figure 4A). In agreement with previous findings (Figure 1A), MG115 and bortezomib failed to block lysosome impairment mediated by alum (Figure 4A). As an alternative way to measure lysosome integrity, we used the lysosomotropic dye acridine orange (AO). The weakly basic dye acridine orange accumulates within acidic endosomes and lysosomes, and is released upon lysosome rupture. We found that the punctate AO pattern observed in untreated cells progressed to a diffuse cytosolic and nuclear staining upon LLOMe exposure indicating a loss of lysosomal integrity (Figure 4B). As expected, the proteasome inhibitor MG115 prevented the AO diffusion

Figure 3. MG115 inhibits cathepsin C activity. (A) The cathepsin C assay was performed in the presence of 1 ng recombinant cathepsin C, the cathepsin C substrate Gly-Arg-AMC, and increasing concentrations of MG115 or the cathepsin C inhibitor Gly-Phe-DMK (GF-DMK). Cathepsin C activity was measured by analyzing Gly-Arg-AMC cleavage at 460 nm. (B) C57BL/6-derived macrophages were exposed to 2.5 mM LLOMe in the presence of increasing concentrations of MG115 or GF-DMK, and cell death was measured by PI exclusion two hours after LLOMe exposure.

CA-074-Me inhibits lysosome-mediated necrosis by inhibiting a factor distinct from cathepsins B and C

The cathepsin B inhibitor, CA-074-Me is the only inhibitor known to block all forms of programmed necrotic cell death [9,22,28,36], including alum and LLOMe-mediated cell death (Figure 1A). Cathepsin B-deficient cells are susceptible to LLOMe-induced cell death (Figure 5A), indicating that cathepsin B is dispensable for LLOMe killing. Accordingly, high concentrations of CA-074-Me, like MG115 and MG132, are required to block LLOMe-mediated cell death [9,22,28,36], suggesting that off-targets are involved in the CA-074-Me block of LLOMe toxicity. We next investigated whether CA-074-Me prevents LLOMe-induced cell death by inhibiting cathepsin C, as observed with MG115. To test this, we incubated recombinant murine cathepsin B or C with their corresponding substrates in the presence of increasing concentrations of CA-074-Me, MG132 and GF-DMK. As CA-074-Me has to be activated by cellular esterase [29], we used its active metabolite CA-074-Me, which does not require esterase cleavage of the methyl-ester group for activation. In contrast to MG115, the cathepsin B inhibitor CA-074-Me did not block cathepsin C activity even at exceeding concentrations (Figure 5B). CA-074-Me, however, blocked the activity of recombinant cathepsin B at concentrations below 1 µM (Figure 5B), consistent with it being a potent cathepsin B inhibitor. As expected GF-DMK blocked cathepsin C, but not cathepsin B (Figure 5B). Surprisingly, MG132 also blocked cathepsin B, and at concentrations that were even lower than those required for blocking cathepsin C (Figure 5B), indicating that MG132 blocks a wide range of proteases. As cathepsin B-deficient cells are susceptible to LLOMe toxicity, we assume that the MG132 block of cathepsin B is merely an epiphenomenon, and not involved in the MG132 inhibition of LLOMe toxicity.

Here we demonstrated that CA-074-Me blocks LLOMe killing in a cathepsin C-independent fashion, while peptide aldehyde proteasome inhibitors act in a cathepsin C-dependent fashion indicating that both inhibitors prevent LLOMe toxicity by targeting distinct regulators. The knockout experiments also indicated that cathepsin B is also not involved in the CA-074-Me block of LLOMe killing. These findings indicated that the cathepsin B inhibitor targets a novel, yet unidentified critical factor in LLOMe-mediated necrosis.

To further analyze how CA-074-Me prevents LMN, we determined the morphological changes of primary murine macrophages following LLOMe challenge in the presence of CA-074-Me. As observed in necrotic cell death mediated by anthrax lethal toxin [32,40], LLOMe triggered morphological changes associated with necrotic cell death, such as a loss of the cellular matrix, loss of organelle structure and the formation of multi-vesicular bodies (Figure 6A). We also challenged primary
macrophages with LLOMe in the presence of increasing CA-074-Me concentrations. LLOMe triggered a very rapid onset of membrane impairment, another hallmark of necrotic cell death as measured by PI exchange and LDH release (Figure 6B, and Figure S2), and proteolysis of IL-1β (Figure 6B). Both necrotic events were efficiently blocked by CA-074-Me. In fact, we found a perfect correlation between cell death induction and processing of proinflammatory proteins (Figure 6B), suggesting a direct linkage between these processes in LLOMe-treated cells.

Summary

Lysosome-mediated necrosis (LMN) is a distinct cell death pathway that could trigger a strong adaptive immune response [9,11,12,24]. Identification of factors controlling LMN will advance our understanding of immune regulators. The phenotype of LMN is characterized by simultaneous membrane impairment and broad proteolysis of proteins [9,11,12,24]. Given the role of the proteasome in multiple forms of necrotic and apoptotic cell death [30,31,32,41] the proteasome presented an attractive regulator for the LMN phenotype. Here we describe that peptide proteasome inhibitors efficiently block lysosome rupture, degradation of proinflammatory proteins and necrotic cell death. While peptide aldehyde proteasome inhibitors and CA-074-Me block an upstream event in LLOMe-treated cells, our findings indicated that they have distinct targets. While peptide aldehyde proteasome inhibitors block LLOMe lysosome rupture and necrotic cell death by blocking cathepsin C, CA-074-Me acts in a cathepsin C-independent fashion and targets a distinct, unidentified mediator of LMN. Our findings suggest that CA-074-Me blocks an event leading to cathepsin C activation in LLOMe-mediated necrosis, and an upstream event in necrotic cell death in general.

Intriguingly, CA-074-Me blocks all known forms of programmed necrotic cell death [9,22,28,36]. In addition to preventing LMN, CA-074-Me also blocks pyroptotic cell death upstream of caspase-1 activation [9,22,28,36], and necroptosis upstream of RIP kinase [22,23]. As with LMN, the doses of CA-074-Me needed to block necrotic cell death are higher than those

Figure 4. The proteasome inhibitor MG115 blocks LLOMe-mediated lysosome rupture. (A) Flow cytometry analysis of LLOMe-, alum- and LT-treated cells. BALB/c-derived macrophages were exposed to 2.5 mM LLOMe, LT (500 ng/ml PA and 250 ng/ml LF), or alum (150 μg/ml) in the absence and presence of 100 μM MG115 and 50 μM bortezomib. Lysosome and membrane integrity were measured using LysoTracker and PI by flow cytometry 2 hours post LLOMe and LT challenge, and 6 hours post alum challenge. The flow cytometry plots are representative images of two experiments each performed in triplicate. (B) C57BL/6-derived macrophages were exposed to 2.5 mM LLOMe in the absence and presence of 100 μM MG115. Analysis of lysosome integrity was determined by acridine orange (AO) staining 2 hours post LLOMe exposure. The above data is representative of three experiments.

doi:10.1371 journal.pone.0095032.g004
are needed to inhibit cathepsin B, as well as many other cysteine cathepsins [11,24]. Our data suggest that the putative target of CA-074-Me may be a common upstream protease and regulator in multiple necrotic cell death pathways, possibly another cysteine cathepsin. However, our studies using a haploid screen and cathepsin-deficient macrophages identified only a single cathepsin, cathepsin C, as essential for LLOMe toxicity [11,24]. However, our findings indicate that a second CA-074-Me-susceptible protease, in addition to cathepsin C, controls early event in lysosome-mediated necrosis. It remains to be shown whether CA-074-Me targets the same protein in each form of programmed necrosis, and identification of this protein will provide significant insights into the fundamental processes controlling necrotic cell death.

Taken together, our findings indicated that a cascade of proteolytic events controls lysosome rupture and necrotic cell death mediated by lysosome-destabilizing agents and other inducers of necrotic cell death. Identification of these early events will be crucial in our understanding of checkpoints controlling necrotic cell death, and ultimately the biological processes effected by necrotic cell death.

**Materials and Methods**

**Chemicals**

MG115, MG132 and nigericin were purchased from Calbiochem (San Diego, CA), and bortezomib (Velcade) was a generous gift from Nereus Pharmaceuticals (San Diego, CA). Bafilomycin A was purchased from LC Laboratories (Woburn, MA). Inject alum purchased from Thermo Scientific (Rockford, IL). NH4Cl was purchased from Fisher Scientific (Pittsburgh, PA). Propidium Iodide was purchased from Sigma (St. Louis, MO). CA-074-Me was purchased from Peptides International (Louisville, KY). CA-074 was a generous gift from Kartik Chandran (Albert Einstein College of Medicine).

**Cell Culture**

Wild type C57BL/6 and BALB/c mice were purchased from Jackson Labs (Bar Harbor, MN). The BALB/c-derived macro-
phage line J774A.1 was purchased from ATCC (Manassas, VA). Bone marrow-derived macrophages were generated from bone marrow derived from femurs and tibias of wild type C57BL/6 and BALB/c mice, and from cathepsin-deficient C57BL/6 mice. We used C56BL/6-derived macrophages for most assays, as macrophages from these strains could be harvested with high efficiency, and these cells are highly susceptible to most inducers of necrotic cell death, including LLOMe, alum and LPS/nigericin. However, C56BL/6-derived macrophages are resistant to necrotic cell death mediated anthrax lethal toxin (LT), which kills macrophages in a strain-dependent fashion. We therefore performed all experiments that included LT with BALB/c macrophages, which are highly susceptible to LT toxicity, but still susceptible to LLOMe, alum and LPS/nigericin-induced cell death. Cathepsin-deficient C57BL/6 mice were generously provided by Drs. Johanna Joyce and Thomas Reinheckel [42,43,44]. BMMs were isolated and grown for 7 days in DMEM, containing 10% FCS, 20% L929 preconditioned media, 1% HEPES, 1% MEM nonessential amino acids, and 0.1% cell-culture grade BME. For the preparation of primary dendritic cells, bone marrow cells were conditioned in RPMI media containing 10% FCS, 1% HEPES, 1% MEM nonessential amino acids, 0.1% Gibco BME, in the presence of 20 ng/ml GM-CSF (Leukine; Berlex, Montville, New Jersey).

Cell death assays

Macrophages were plated in 96-well plates at 1×10⁶ cells/ml, and cell death was determined by measuring membrane impairment by analysis of propidium iodide exclusion, or by measuring LDH activity, at specified time points. Propidium iodide (PI) was added to a final concentration of 30 μM 10 min prior to analysis. PI exclusion assays were performed in phenol-red-free DMEM and analyzed with a Wallac 1420 Multilabel Counter, Victor 3 plate-reader (Perkin-Elmer Life, Mountain View, CA). The LDH activity was measured using the CytotoxOne kit (Promega, Madison, WI) according to the manufacturer’s description.

Flow cytometry, immunoblotting and confocal microscopy

For flow cytometry, bone marrow-derived macrophages were labeled with CD11b-PE, lysosome integrity was measured with LysoTracker Green and acridine orange, and membrane impairment was determined by using PI. Cells were fixed in 1% paraformaldehyde, and analyzed using a BD LSRII flow cytometer. For immunoblotting, macrophage supernatants were collected and spun down at 300 g for 10 min at 4°C. For cell lysate preparations, RIPA buffer (Boston Bioproducts, MA) containing protease inhibitor cocktail (Roche, Basel, Switzerland) was added to cells and incubated at 4°C for 10 min. Cell lysates were collected and spun at 13,000 rpm for 10 min at 4°C.
Supernatants and lysates were placed in water bath at 100°C for three min, and run on 12% Tris-HCl gels (Bio-Rad). Gels were then transferred onto PVDF membranes with a semi-dry transfer apparatus (Bio-Rad). Membranes were probed with anti-caspase-1, IL-1β and actin antibodies (R and D Technologies, Kingstown, RI). Antibodies against goat were obtained from Santa Cruz (Santa Cruz, CA). Confocal microscopy using acridine orange was performed as described previously [44].

In vitro cathepsin cleavage assays

Recombinant active murine cathepsin B and cathepsin C were purchased from R&D Systems (Minneapolis, MN), and the in vitro cathepsin assays were performed according to the manufacturer’s description. The cathepsin B substrate Arg-Arg-AMC and the cathepsin C substrate Gly-Phe-AMC were purchased from Bachem (Torrance, CA), and the cathepsin B inhibitor, Gly-Phe-diazomethylketone (Gly-Phe-DMK), was from MP Biomedicals (Solon, OH). The cathepsin B assay was performed with 5 μg of recombinant active murine cathepsin B in the presence of 200 μM of the cathepsin B substrate Arg-Arg-AMC and various inhibitors. Cathepsin B was activated with 1 mM dithiothreitol and 0.5% Triton X-100 for 1 hour. The cathepsin C assay was performed with 1 μg of recombinant active murine cathepsin C in the presence of 200 μM of the cathepsin C substrate Gly-Phe-AMC and various inhibitors. The generation of free AMC was determined by measuring excitation and emission wavelengths of AMC and various inhibitors. Cathepsin B was activated with 1 mM dithiothreitol and 0.5% Triton X-100 for 1 hour. The cathepsin C assay was performed with 1 μg of recombinant active murine cathepsin C in the presence of 200 μM of the cathepsin C substrate Gly-Phe-AMC and various inhibitors. The generation of free AMC was determined by measuring excitation and emission wavelengths of AMC and various inhibitors. Cathepsin B was activated with 1 mM dithiothreitol and 0.5% Triton X-100 for 1 hour. The cathepsin C assay was performed with 1 μg of recombinant active murine cathepsin C in the presence of 200 μM of the cathepsin C substrate Gly-Phe-AMC and various inhibitors. The generation of free AMC was determined by measuring excitation and emission wavelengths of AMC and various inhibitors. Cathepsin B was activated with 1 mM dithiothreitol and 0.5% Triton X-100 for 1 hour. The cathepsin C assay was performed with 1 μg of recombinant active murine cathepsin C in the presence of 200 μM of the cathepsin C substrate Gly-Phe-AMC and various inhibitors. The generation of free AMC was determined by measuring excitation and emission wavelengths of AMC and various inhibitors.

Transmission electron microscopy

Samples were fixed with 2% glutaraldehyde in sodium cacodylate buffer, pH 7.4, and post fixation was performed with 1% osmium tetroxide, followed by 2% uranyl acetate treatment as described previously [44]. After dehydration through a graded series of ethanol washes, samples were embedded in LX112 resin (LADD Research Industries). Ultrathin sections were cut on a Reichert Ultracut UC7, stained with 25% uranyl acetate followed by lead citrate, and examined with a JEOL 1200EX transmission electron microscope at 80 kV.

Ethics statement

The animal study protocol (#503-2012) was reviewed and approved by the Animal Care and Use Committee of the National Institutes of Health.

Supporting Information

Figure S1 BALB/c-derived macrophages were exposed to anthrax lethal toxin (LT: 500 ng/ml PA and 250 ng/ml LF) in the presence of increasing concentrations of MG115 (A), MG132 (B), or bortezomib (C). Control cells were exposed to inhibitor only. Cell death was measured by PI exclusion two hours after LT exposure, and relative cell death levels are shown. The above data was performed in triplicate.

Figure S2 C57BL/6-derived macrophages were exposed to 2.5 mM LLOMe in the presence and absence of 100 μM CA-074-Me, and cell death was measured by LDH release (A) and PI exclusion (B) at different time points post LLOMe exposure.

Author Contributions

Conceived and designed the experiments: KB JD FD. Performed the experiments: AK HI LJ SM JB. Analyzed the data: JD FK KC. Contributed reagents/materials/analysis tools: JB KC DF. Wrote the paper: JB FD.

References

1. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G (2009) The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10: 241–247.
2. Ting JPY, Willingham SB, Bergotto RT (2008) NLRs at the intersection of cell death and immunity. Nat Rev Immunol 8: 372–379.
3. Li HF, Ambade A, Re F (2009) Cutting Edge: Necrosis Activates the NLRP3 Inflammasome. J Immunol 183: 1520–1532.
4. Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, et al. (2009) Necrotic cells orchestrate a programmed form of cell demise: signalling cascades, important mediators and disease pathogenesis. Nat Rev Immunol 8: 279–289.
5. Festjens N, Vaesens Bergh T, Vandenabeele P (2006) Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta 1757: 1371–1376.
6. Baso S, Binder RJ, Suto R, Anderson K, Sircastava PK (2009) Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NFκB pathway. Cell Stress & Chaperones 5: 373–374.
7. Jacobson LS, Lima H Jr, Goldberg MF, Goecheva V, Tsiaperov V, et al. (2013) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228–232.
8. Koon H, Rock KL (2008) How dying cells alert the immune system to danger. Nat Rev Immunol 8: 20388–20393.
9. Kool M, Soullie T, van Nimwegen M, Willart MA, Muskens F, et al. (2008) anthrax lethal toxin kills macrophages in a strain-specific manner by apoptosis or caspase-1-mediated necrosis. Cell Cycle 7: 50–56.
10. Christofferson DE, Yuan JY (2010) Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 22: 263–268.
11. Brennan MA, Cookson BT (2009) Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Micro 8: 1812–1825.
26. Reinheckel T (2013) On the road to inflammation: linking lysosome disruption, lysosomal protease release and necrotic death of immune cells. Cell Cycle 12: 1994.

27. Guicciardi ME, Leist M, Gores GJ (2004) Lysosomes in cell death. Oncogene 23: 2831–2890.

28. Hornung V, Bauerfeind F, Halle A, Samstad EO, Kono H, et al. (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9: 847–856.

29. Newman ZL, Leppila SH, Moayeri M (2009) CA-074Me protection against anthrax lethal toxin. Infect Immun 77: 4327–4336.

30. Orłowski RZ (1999) The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 6: 303–313.

31. Squires RC, Muehlbauer SM, Brojatsch J (2007) Proteasomes control caspase-1 activation in anthrax lethal toxin-mediated cell killing. J Biol Chem 282: 34260–34267.

32. Muehlbauer SM, Lima H Jr, Goldman DL, Jacobson LS, Rivera J, et al. (2010) Proteasome inhibitors prevent caspase-1-mediated disease in rodents challenged with anthrax lethal toxin. Am J Pathol 177: 735–743.

33. Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem & Biol 8: 739–758.

34. Turk BE (2007) Manipulation of host signalling pathways by anthrax toxins. The Biochem J 402: 405–417.

35. Brojatsch J, Casadevall A, Goldman DL (2014) Molecular determinants for a cardiovascular collapse in anthrax. Front Biosci 6: 139–147.

36. Hentze H, Lin XY, Choi MS, Porter AG (2003) Critical role for cathepsin B in mediating caspase-1-dependent interleukin-16 maturation and caspase-1-independent necrosis triggered by the microbial toxin nigericin. Cell Death Differ 10: 956–968.

37. Wang F, Krai P, Deu E, Bibb B, Lauritzen C, et al. (2011) Biochemical characterization of Plasmodium falciparum dipeptidyl aminopeptidase 1. Mol Bioch Parasitol 175: 10–20.

38. Thiele DL, Lipsky PE (1990) The action of leucyl-leucine methyl ester on cytotoxic lymphocytes requires uptake by a novel dipeptide-specific facilitated transport system and dipeptidyl peptide I-mediated conversion to membrane lytic products. J Exp Med 172: 183–194.

39. Thiele DL, Lipsky PE (1990) Mechanism of L-leucyl-L-leucine methyl ester-mediated killing of cytotoxic lymphocytes: dependence on a lysosomal thiol protease, dipeptidyl peptide 1, that is enriched in these cells. Proc Natl Acad Sci U S A 87: 83–87.

40. Alleeche A, Squires RC, Muehlbauer SM, Lisanti MP, Brojatsch J (2006) Mitochondrial impairment is a critical event in anthrax lethal toxin-induced cytolysis of murine macrophages. Cell Cycle 5: 100–106.

41. Newman Z, Leppila S, Moayeri M (2009) CA-074Me protection against anthrax lethal toxin. Infect Immun: 1–43.

42. Halangk W, Lerch MM, Brandt-Nedelev B, Roth W, Ruthenbuerger M, et al. (2000) Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. The Journal of clinical investigation 106: 773–781.

43. Roth W, Deussing J,Botchkarev VA, Pauly-Evers M, Saftig P, et al. (2000) Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and perturbation of hair follicle cycling. FASEB J 14: 2075–2086.

44. Diaz-Griffero F, Hoschandler SA, Brojatsch J (2002) Endocytosis is a critical step in entry of subgroup B avian leukemia viruses. J Virol 76: 12866–12876.